不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
基线 PD-L1 表达和 TIL（肿瘤浸润淋巴细胞）状态可预测不可切除局部晚期非小细胞肺癌患者放化疗后度伐利尤单抗巩固治疗的疗效
英文原题：Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the efficacy of durvalumab consolidation therapy after chemoradiotherapy in unresectable locally advanced patients with non-small-cell lung cancer.
查看英文原题
Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the efficacy of durvalumab consolidation therapy after chemoradiotherapy in unresectable locally advanced patients with non-small-cell lung cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
基线 PD-L1+ 和 TIL 高可能是 CRT 后序贯 durvalumab 疗效的预测标志物。
研究思路结论见上方概要
背景
放化疗（CRT）后度伐利尤单抗治疗改善了不可切除局部晚期非小细胞肺癌（LA-NSCLC）的预后。本研究旨在评估基线时免疫相关肿瘤微环境（TME）状态是否与疗效相关。
方法
这项回顾性研究评估了免疫相关的TME因素，包括肿瘤细胞上程序性细胞死亡配体1（PD-L1）（克隆号：22C3）的表达以及CD8阳性TIL（肿瘤浸润淋巴细胞）（TILs）的密度，在仅接受CRT治疗（单纯CRT组）和接受CRT后序贯durvalumab治疗（Durva组）的不可切除LA-NSCLC患者中，于CRT前进行检测。
结果
共纳入551例患者（Durva组N=113）。Durva组的无进展生存期（PFS）显著长于单纯CRT组（未达到[NR] vs 12.9个月；p=0.002）。在单纯CRT组中，PD-L1表达和TIL状态均未影响PFS；相反，在Durva组中，高密度CD8阳性TILs（TIL高密度100/mm²）和PD-L1阳性表达（肿瘤比例评分1%；PD-L1+）与更长的PFS显著相关（TIL：NR vs 9.5个月；p=0.002；PD-L1：NR vs 7.7个月；p=0.003）。另一方面，在表皮生长因子受体突变或间变性淋巴瘤激酶重排的患者中，两组之间的PFS无显著差异（Durva vs 单纯CRT：9.9个月 vs 14.0个月；p=0.77）。
展开英文摘要原文
BACKGROUND
Chemoradiotherapy (CRT) followed by durvalumab treatment improved prognosis in unresectable locally advanced non-small-cell lung cancer (LA-NSCLC). This study aimed to evaluate whether the status of the immune-related tumour microenvironment (TME) at baseline associates with the efficacy.
METHODS
This retrospective study evaluated immune-related TME factors, including programmed cell death ligand 1 (PD-L1) (clone: 22C3) expression on tumour cells and the density of CD8-positive tumour-infiltrating lymphocytes (TILs) at pre-CRT in patients with unresectable LA-NSCLC treated with CRT only (CRT alone group) and those treated with CRT followed by durvalumab (Durva group).
RESULTS
A total of 551 patients were included (N = 113 in the Durva group). Progression-free survival (PFS) in the Durva group was significantly greater than that in the CRT alone group (not reached [NR] vs 12.9 months; p = 0.002). In the CRT alone group, neither PD-L1 expression nor TIL status affected PFS; in contrast, in the Durva group, high density of CD8-positive TILs (TIL High 100/mm 2 ) and PD-L1-positive expression (tumour proportion score 1%; PD-L1+) was significantly associated with longer PFS (TIL: NR vs 9.5 months; p = 0.002; and PD-L1: NR vs 7.7 months; p = 0.003). On the other hand, in patients with epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements, there was no significant difference in PFS between the groups (Durva vs CRT alone: 9.9 months vs 14.0 months; p = 0.77).
CONCLUSIONS
PD-L1+ and TIL High at baseline could be predictive markers of the efficacy of CRT followed by durvalumab.
论文信息
- 作者
- Shirasawa M、Yoshida T、Imabayashi T、Okuma K、Matsumoto Y、Masuda K、Shinno Y、Okuma Y
- 第一作者单位
- Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan; Department of Respiratory Medicine, Kitasato University School of Medicine, 1-15-1, Kitasato, Minami-ku, Sagamihara City, Kanagawa, 252-0375, Japan. Electronic address: mshirasa@ncc.go.jp.Japan
- 通讯作者单位
- Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan; Department of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. Electronic address: tatyoshi@ncc.go.jp.Japan
- 文献类型
- 非美国政府资助研究
- 期刊
- European journal of cancer (Oxford, England : 1990)2022 Feb
- 原文标识
- PubMed 34936940 · DOI 10.1016/j.ejca.2021.11.013